Text Size

A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Otsuka Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01631825
First received: June 25, 2012
Last updated: June 27, 2012
Last verified: June 2012
History of Changes
  Purpose
  • To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in a multi-center, open-label uncontrolled study.
  • To investigate efficacy of SPM 962 in an exploratory manner.

Condition Intervention Phase
Parkinson's Disease
 Drug: SPM 962
 Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label Long-term Extension Trial From Phase III of SPM962 (243-08-002) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa

Resource links provided by NLM:

Drug Information available for: Rotigotine
U.S. FDA Resources

Further study details as provided by Otsuka Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • Incidence and severity of adverse events, vital signs, and laboratory parameters [ Time Frame: Up to 54 weeks after dosing ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 sum score [ Time Frame: Up to 54 weeks after dosing ] [ Designated as safety issue: No ]
  • UPDRS Part 2 sum score [ Time Frame: Up to 54 weeks after dosing ] [ Designated as safety issue: No ]
  • Absolute time spent "off" [ Time Frame: Up to 54 weeks after dosing ] [ Designated as safety issue: No ]
    Mean number of hours in "off state" during a 24-hour period.


Enrollment: 321
Study Start Date: October 2009
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SPM 962
SPM 962 transdermal patch
 Drug: SPM 962
SPM 962 transdermal patch once a daily up to 36.0 mg/day
Other Name: rotigotine

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject completed the preceding trial 243-08-001.

Exclusion Criteria:

  • Subject discontinued from the preceding trial 243-08-001.
  • Subject had a serious adverse event which association with the investigational drug was not ruled out during trial 243-08-001.
  • Subject has a persistent serious adverse event at the baseline, which was observed and association with the investigational drug was ruled out during trial 243-08-001.
  • Subject had persistent confusion, hallucination, delusion or excitation during trial 243-08-001.
  • Subject has abnormal behavior such as obsessive-compulsive disorder and delusion in 243-08-001 study.
  • Subject showed serious or extensive application site reactions beyond the application site in the 243-08-001 study.
  • Subject has orthostatic hypotension or a systolic blood pressure (SBP) <= 100 mmHg and has a decrease of SBP from spine to standing position >= 30 mmHg at baseline.
  • Subject has a history of epilepsy, convulsion etc. during trial 243-08-001.
  • Subject develops serious ECG abnormality at the baseline.
  • Subject has QTc-interval >= 500 msec at the baseline or subject has an increase of QTc-interval >= 60 msec from the baseline in the trial 243-08-001 and has a QTc-interval > 470 msec in female or > 450 msec in male at the baseline.
  • Subject had a serum potassium level < 3.5 mEq/L at the end of the taper period in trial 243-08-001.
  • Subject has a total bilirubin >= 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or ? 100 IU/L) at the end of the period in trial 243-08-001.
  • Subject had BUN >= 30 mg/dL or serum creatinine >= 2.0 mg/dl at the end of the taper period in trial 243-08-001.
  • Subject who plans pregnancy during the trial.
  • Subject is unable to give consent.
  • Subject is judged to be inappropriate for this trial by the investigator for the reasons other than above.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01631825

Locations
Japan
Chubu Region, Japan
Chugoku Region, Japan
Hokkaido Region, Japan
Kanto Region, Japan
Kinki Region, Japan
Kyushu Region, Japan
Shikoku Region, Japan
Tohoku Region, Japan
Sponsors and Collaborators
Otsuka Pharmaceutical Co., Ltd.
Investigators
Study Director: Kyoji Imaoka, Mr Otsuka Pharmaceutical Co., Ltd.
  More Information

No publications provided

Responsible Party: Otsuka Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT01631825     History of Changes
Other Study ID Numbers: 243-08-002
Study First Received: June 25, 2012
Last Updated: June 27, 2012
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Otsuka Pharmaceutical Co., Ltd.:
SPM 962
rotigotine
Parkinson's disease
concomitant use of L-dopa

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
 N 0437
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 23, 2013